CORRECTION: Chimerix Q2 EPS $(0.21) Beats $(0.24) Estimate, Sales $26.00K Miss $230.00K Estimate; Capital Available to Fund Operations Is $233M
Portfolio Pulse from Benzinga Newsdesk
Chimerix (NASDAQ:CMRX) reported Q2 EPS of $(0.21), beating the estimate of $(0.24) by 12.5%. However, the company's sales of $26.00K missed the estimate of $230.00K by 88.7%. This represents a 94.09% decrease from the same period last year. The company has $233M available to fund operations.
August 04, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Chimerix's Q2 EPS beat estimates but sales significantly missed, indicating potential operational issues. The company has $233M in capital available.
While Chimerix beat EPS estimates, the significant miss on sales could indicate operational issues or decreased demand for its products. This could negatively impact the stock price in the short term. However, the company's available capital of $233M may provide some buffer.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100